retatrutide clinical trials phase Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and A Study of Retatrutide (LY3437943)

The half-life of Dihexa is quite long, with 50% of the peptide drug out of your system in 12.8 days after it has been administered

The #uncomfortable #truth This 2026 BMJ systematic review and #metaanalysis delivers one of the clearest reality checks yet on weight regain after stopping weight-management medications (WMMs), including GLP-1 and dual incretin therapies

MOTS-C levels in humans decline by approximately 21% between ages 30 and 80

Emerging evidence suggests benefits in alcohol use disorder, smoking cessation, asthma, psoriasis, inflammatory bowel disease, depression, food cravings, binge-eating behaviour, and potentially even neurodegenerative disease